Stay updated on Pembrolizumab Plus MK-4830 in Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Plus MK-4830 in Ovarian Cancer Clinical Trial page.

Latest updates to the Pembrolizumab Plus MK-4830 in Ovarian Cancer Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoNo Change Detected
- Check21 days agoNo Change Detected
- Check28 days agoChange DetectedSignificant update: added current operating status notice, current date, expanded study listing header with 2025-09-11 details, and revision v3.2.0; removed old date 2024-12-17 and revision v3.1.0.SummaryDifference14%

- Check35 days agoChange DetectedChanged the revision from v3.0.2 to v3.1.0, indicating a minor version update with no other content changes.SummaryDifference0.2%

- Check49 days agoChange DetectedCore content now shows Revision: v3.0.2 replacing v3.0.1. The Back to Top link was removed (minor UI change).SummaryDifference0.6%

- Check57 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes to core content or important information.SummaryDifference0.6%

- Check64 days agoChange DetectedThe web page has undergone significant updates, including the addition of a facility name and location, while removing specific location details such as state, country, and city information.SummaryDifference38%

- Check78 days agoChange DetectedThe web page has been updated from version v2.16.11 to v2.16.12.SummaryDifference0.3%

Stay in the know with updates to Pembrolizumab Plus MK-4830 in Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Plus MK-4830 in Ovarian Cancer Clinical Trial page.